Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 7241
Country/Region: Tanzania
Year: 2015
Main Partner: PharmAccess Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USDOD
Total Funding: $4,275,868 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $255,588
Care: Orphans and Vulnerable Children (HKID) $235,971
Care: TB/HIV (HVTB) $100,084
Care: Pediatric Care and Support (PDCS) $193,554
Laboratory Infrastructure (HLAB) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $608,995
Testing: HIV Testing and Counseling (HVCT) $240,900
Sexual Prevention: Other Sexual Prevention (HVOP) $35,640
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $176,225
Treatment: Adult Treatment (HTXS) $2,235,357
Treatment: Pediatric Treatment (PDTX) $193,554
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 225
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 19,034
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 4,258
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 600
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 89,523
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2016 3
LAB_CAP By clinical laboratories 2016 26
LAB_CAP By Point-of-care testing sites 2016 2
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 28
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2016 1,070
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 4
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 940
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 4
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 940
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 2
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 255
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 2
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 685
PMTCT_ARV Sum of New and Current disaggregates 2016 4
PMTCT_ARV Sum of New and Current disaggregates 2016 940
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 436
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 206
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 642
PMTCT_EID Sum of Infant Age disaggregates 2016 642
PMTCT_STAT By: Known positives at entry 2016 2
PMTCT_STAT By: Known positives at entry 2016 255
PMTCT_STAT By: Number of new positives identified 2016 2
PMTCT_STAT By: Number of new positives identified 2016 685
PMTCT_STAT Number of new ANC and L&D clients 2016 49
PMTCT_STAT Number of new ANC and L&D clients 2016 13,203
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 33
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 12,735
PMTCT_STAT Sum of Positives Status disaggregates 2016 4
PMTCT_STAT Sum of Positives Status disaggregates 2016 940
PP_PREV Age/sex: 15-19 Female 2016 600
PP_PREV Age/sex: 20-24 Female 2016 600
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 1,200
PP_PREV Sum of Age/Sex disaggregates 2016 1,200
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 225
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 19,034
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 18,090
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 209
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 17,714
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 4,108
TX_NEW Pregnancy status 2016 316
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 87
VMMC_CIRC By Age: 10-14 2016 4,045
VMMC_CIRC By Age: 15-19 2016 2,250
VMMC_CIRC By Age: 20-24 2016 1,344
VMMC_CIRC By Age: 50+ 2016 94
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 8,981
VMMC_CIRC Sum of age disaggregates 2016 7,733
Cross Cutting Budget Categories and Known Amounts Total: $360,000
Human Resources for Health $80,000
Motor Vehicles: Purchased $80,000
Gender: Gender Based Violence (GBV) $100,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $100,000
Increase gender-equitable access to income and productive resources, including education
Implementation
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation